COMMUNIQUÉS West-GlobeNewswire

Regeneron Announces Investor Conference Presentations
20/04/2026
TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: • BofA Securities Health Care Conference 2026 at 10:00 a.m. PT (1:00 [...]
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
20/04/2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/04/2026
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase [...]
Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定，并通过 IND 审评
21/04/2026
FDA 授予 Daretabart (hu1418K322A) 快速通道认定资格，以解决高危神经母细胞瘤领域存在的重大未满足医疗需求，允许该药物进入加速评审和滚动审评流程 FDA 通过新药临床研究 (IND) 申请后，即可在高危神经母细胞瘤复发及难治性患者中启动 SHINE II/III 期临床试验 Daretabart (hu1418K322A) 第一个商业化规模 GMP 生产批次已顺利完成项目基于 II 期的积极数据， [...]
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
20/04/2026
Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and development of novel [...]
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
20/04/2026
SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
20/04/2026
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced [...]
Moonbird Claims Evaluated: Guided Breathing Therapy Device for Meditation-Like Calming Benefits for Relaxation & Sleep Support
21/04/2026
A 2026 informational overview of Moonbird's tactile breathing coach technology, EEG brain scan research references, real-time HRV biofeedback, pricing structure, and what prospective buyers should know before ordering [...]
NADP appoints first dentist to lead dental informatics program
20/04/2026
Dr. Lauren E. Gritzer named dental informatics and plan operations director DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- The National Association of Dental Plans has appointed Lauren Gritzer, DDS, MPH, as director of [...]
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
20/04/2026
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that [...]
Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy
20/04/2026
First‑in‑class DARKFOX‑targeting bispecific T cell engager: ENA101 is designed to selectively recognize the DARKFOX‑A3 peptide presented by HLA‑A*03:01, a highly prevalent HLA allele, enabling precise redirection of T [...]
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
20/04/2026
WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary [...]
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
20/04/2026
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” [...]
FLYTE EMERGES AS DIRECT BENEFICIARY AS RISING FUEL COSTS DRIVE AIRLINE RETREAT FROM SHORT-HAUL ROUTES
20/04/2026
Major Carriers Accelerate Route Cuts as Economics Break Down, Creating Multi-Billion-Dollar Opportunity in Regional Air Mobility Flyte Expands Focus on High-Frequency Short-Haul Routes to Capture Surging Demand as [...]
IBA – ACQUISITION OF OWN SHARES
20/04/2026
Louvain-la-Neuve, Belgium, April 20 th , 2026 – 9 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
AB Science : Nouvelle publication sur medrxiv démontrant des bénéfices substantiels en termes de survie et de qualité de vie préservée avec le masitinib chez les patients atteints de SLA
20/04/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR MEDRXIV DÉMONTRANT DES BÉNÉFICES SUBSTANTIELS EN TERMES DE SURVIE ET DE QUALITÉ DE VIE PRÉSERVÉE AVEC LE MASITINIB CHEZ LES PATIENTS ATTEINTS DE [...]
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
20/04/2026
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Masitinib treatment [...]
ViriFlow Claims Evaluated: The Prostate-Supporting Formula for Men That Actually Works in Viri Flow Drops Reviewed
20/04/2026
A 2026 informational overview of ViriFlow's hard water mineral theory, saw palmetto and iodine-rich seaweed blend research, proprietary blend dosing transparency, liquid dropper format considerations, prostate [...]
IBA – ACQUISITION D’ACTIONS PROPRES
20/04/2026
Louvain-la-Neuve, Belgique, 20 avril 2026 – 21h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]

Pages